about
A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's diseaseAnalysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individualsToward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseEvidence for an association between KIBRA and late-onset Alzheimer's diseaseGAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriersPeripheral delivery of a ROCK inhibitor improves learning and working memory.The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriersUshering in the study and treatment of preclinical Alzheimer diseaseFluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatmentsRarity of the Alzheimer disease-protective APP A673T variant in the United StatesCalmodulin-binding transcription activator 1 (CAMTA1) alleles predispose human episodic memory performanceOrigin of the PSEN1 E280A mutation causing early-onset Alzheimer's diseaseBiochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's diseaseQuantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study GroupCommon variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.A genome-wide association study of depressive symptoms2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.Subjective cognitive decline: self and informant comparisonsCommon variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study.Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association studyComparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry.Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional studyAssociation of amyloid burden, brain atrophy and memory deficits in aged apolipoprotein ε4 mice.Clustering huge data sets for parametric PET imaging.The role of biomarkers in clinical trials for Alzheimer diseaseCollaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trialsLinking brain imaging and genomics in the study of Alzheimer's disease and aging.Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set.Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain.Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathologyHigh-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation.Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Reanalysis of the obesity-related attenuation in the left dorsolateral prefrontal cortex response to a satiating meal using gyral regions-of-interest.A potential role for the midbrain in integrating fat-free mass determined energy needs: An H2 (15) O PET study.Clinical impact of updated diagnostic and research criteria for Alzheimer's disease.Association between trait emotional awareness and dorsal anterior cingulate activity during emotion is arousal-dependent.Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease.
P50
Q21146622-B934F097-E040-4D52-BD2F-6447405A0A9AQ24305513-D29F03DF-AEBE-4097-86A8-1B58A7AB7B9DQ24595802-A54109E6-7A30-4D74-8292-44548B678DDDQ24598464-9F464BBE-EC07-4E37-88AB-E29C63C92CC9Q24654145-A966CC31-3090-42D8-A73D-67F3F26E6438Q24658098-F9703025-9111-439A-A1C6-F965FD56E46BQ26801654-E399BB4F-A0C0-463B-A38A-3C2F6E970684Q26849380-C3B30447-E65E-4DCB-A97D-2D5728B578A7Q27014791-60A1E632-FD64-4744-851C-C0D1CDA38C86Q27024117-7C85749E-7770-4755-868E-06ABB89167C7Q27346292-FDDA0F17-A74A-481F-B329-B5E81FE8F613Q28300065-5CBB6E5A-174F-49EB-88C3-6113D6D1A55CQ28302044-9EAF510F-006F-4137-AEAD-0F9FED2B0F54Q28542628-BB6ACF8D-0ACC-4D66-AC45-DCB668AA8D6BQ28550984-BADD6EE2-27C8-465B-87CD-82AFAE0492C8Q28943325-6011BA01-11E5-40CC-8F55-363EDCF37245Q28943434-72976884-788B-4D50-A362-5A8A59DF8A25Q30303063-8FD1AE3B-FE02-4A72-B389-AC4E90A53DC3Q30421568-BA1F32B5-F88A-4979-859C-B278D5D189D8Q30434949-8DA5AD68-3752-4D92-9691-0AE36FF44F9BQ30435790-A729C785-0908-4256-9D6F-3BD771DDA5BDQ30459046-4258830F-3786-45F2-B2E4-10A310807CF5Q30476040-55A896FF-B38B-48F9-9F60-EE6DF464C189Q30529034-A8D83B12-2740-4075-8A5D-BF7DFF18F1ACQ30791912-7D800D01-11A1-4F7D-9D6A-9C6852C7B52FQ30882499-74F05640-2A2A-4D7B-AC98-F8782760D578Q31032781-BCF43394-9CDB-43EC-8649-564C0D0380F2Q31093236-CAFB4F70-182D-4301-B2A0-A3915F825ADBQ31108276-863628C2-B1FA-4B08-8E72-8EE6B9B42FC6Q31146509-60457122-A31C-41B1-9874-49D7D8FAAA07Q33262303-F96F20E1-A29B-4979-BB56-9F7925A6A789Q33323272-69A75967-E8CA-41B2-888C-6C5BE71BCD54Q33345759-EDE4F228-EDB9-484E-9318-DF31FC997BD9Q33523403-0EFE011B-D94F-4B69-9D31-5AC2DD216083Q33559175-74299994-CFA1-4314-82D4-88819B9D160FQ33591995-374D86CA-497B-4561-B92A-DB304D32DB84Q33619518-640FB7A3-0F6B-409D-B5C3-F6C94CBDD236Q33640939-DD42810D-141A-4AD6-BF2E-A907DB7CACD3Q33651937-D19C4243-9F24-4E62-81AB-918E5C6B19DFQ33654605-6CCEC862-FAF8-40B1-AD85-623FEC0B9E07
P50
description
psychiater
@nl
psychiatrist and CEO of Banner Research
@en
name
Eric M. Reiman
@ast
Eric M. Reiman
@en
Eric M. Reiman
@es
Eric M. Reiman
@nl
type
label
Eric M. Reiman
@ast
Eric M. Reiman
@en
Eric M. Reiman
@es
Eric M. Reiman
@nl
prefLabel
Eric M. Reiman
@ast
Eric M. Reiman
@en
Eric M. Reiman
@es
Eric M. Reiman
@nl
P1153
7005957089
P166
P21
P214
2760148705745437080002
P31
P735
P7859
viaf-2760148705745437080002